Efficacy of Ursodeoxycholic Acid (UDCA) in Patients With Type 2 Diabetes
Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of ursodeoxycholic acid (UDCA) compared
to placebo on biomarkers of oxidative stress, inflammation, and endothelial dysfunction in
patients with type 2 diabetes mellitus (T2DM) who are treated with metformin but did not meet
the target HbA1C < 7%.